er F

For booking details & registration fees please refer to the last page or visit: http://www.proteins-congress.com/marketing

Protein Purification Custom Protein Production Screening Technologies

Custom Antibody Production Antibody Purification

Antibody Design

Recombinant Proteins Monoclonal Antibodies Imaging Tools

High Throughput Platforms Immunoassay Kits Protein Library Design

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Protein Science Protein Engineering Protein Characterisation

Protein Purification Protein Biochemistry Antibody Discovery

Antibody Optimisation Antibody Technologies Antibody Engineering

Biologics Screening Therapeutic Discovery Alternative Scaffolds

Benefits to Attending

Hear from and meet with the key innovators in proteins & antibodies.

Attendees include: Vice President, AstraZeneca; Vice President, UCB, Vice President, MedImmune

Discover collaborative solutions to protein engineering, designs and

selection. Our highly established event will bring together key opinion

leaders to discuss novel approaches to protein engineering, improving

protein half-life extension and updates in antibody structure and dynamics

Discuss the latest innovations in protein & antibody therapeutics.

Protein therapeutics case studies will include the areas of oncology,

cancer & viral diseases. Updates in antibody discovery and optimisation

will also be addressed

Examine advancements in protein analytics. Hear updates in protein

characterisation, structure and novel approaches to express proteins

utilising cell-based and bacterial systems

Unparalleled networking opportunities. The two-day congress offers

dedicated networking breaks creating an interactive platform for scientific

discussions and 1-1 meetings. The exhibition hall and poster presentation

spaces offer a relaxed and professional environment for discussion

A high quality programme devised with the help of our esteemed

advisory board. Presentations will cover key updates in protein science,

protein stability, alternative scaffolds as well as evaluating different protein

expression technologies

Featuring two new streams on protein & antibody biotherapeutics

Co-located with the highly anticipated 4th Annual Peptides Congress

2017 Speakers Include…

Bohong Zhang Lorenz Mayr Orla Cunningham Shire Pharmaceuticals Inc. AstraZeneca Pfizer Inc.

Meet Senior Decision Makers

400 senior attendees from leading pharmaceutical, biopharmaceutical, academics, CRO and solution provider companies will be attending. Meet Senior VPs, Directors, & Managers with the following job titles:

Proteins & Antibodies Congress Day 1 Stream 1 – Advances in Protein Engineering, Design & Selection

Novel approaches to protein engineering

Improving protein half-life extension, potency & selectivity

Developability of proteins through innovative engineering and design approaches

Contribution of advanced computational design and development of biocatalysts to protein engineering

Day 2 Stream 1 – Antibody Development, Engineering & Design

Updates in antibody structure and dynamics

Generation of antibody diversity

Antibody effector mechanisms

Improvements in antibody drug conjugates

Featured Streams on Protein & Antibody Biotherapeutics Day 1 Stream 2 – Antibody Biotherapeutics

Accelerating antibody discovery & optimisation: o Bispecific antibodies o Monoclonal antibodies o Antibody drug conjugates

Cutting edge technologies for antibody discovery

T cell redirection strategies

Targeting immune checkpoints

Case studies from the area of immunotherapy

Day 2 Stream 3 – Protein & Antibody Biotherapeutics

Case studies from the areas of: o Oncology diseases o Neurotoxins to treat various types of diseases o Autoimmune diseases o Inflammation

Overcoming immunogenicity and aggregation hurdles

Improving protein stability

Alternative scaffolds: challenges & opportunities

Updates in fusion proteins

Day 2 Stream 2 – Cloning, Expression, Purification & Analytics

New strategies to improve protein expression

Updates in protein purification

Updates in crystallisation technologies

Recent advancements in protein characterisation

Detection of antibodies by LC/MS

Evaluating different protein expression technologies

Updates in protein expression utilising cell-based and bacterial systems

Complimentary Webinar:

Advances In Protein & Antibody Biotherapeutics, 7th February 2017. Register for free.

Next Generation Antibody Drug Conjugates, 26th January 2017. Register for free.

Improved Non-Invasive Routes Of Administration Of Peptides, 16th February 2017. Register for free.

For more information please contact marketing@oxfordglobal.co.uk

If you’re on Twitter, make sure to follow us @ProteinCongress and join the Congress conversation using #Proteins2017

2017 Confirmed Speakers Include:

Lorenz Mayr, Vice President, Biological Reagents & Assay Development, AstraZeneca

Rene Hoet, Vice President, Global Biologics, Bayer

Rakesh Dixit, Vice President, Research & Development, MedImmune

Alastair Lawson, Vice President, Structural Biology, UCB

Kristen Picha, Scientific Director, Janssen BioTherapeutics, Janssen R&D

Benno Rattel, Executive Director, Amgen

Kalpit Vora, Director, Infectious Disease and Vaccine Based Research, Merck & Co., Inc.

Andrew Goodearl, Director, AbbVie

Rudolf de Wildt, Director, Biopharm R&D & Head of Lead Discovery, GlaxoSmithKline

Yan Wu, Director and Principal Scientist, Genentech

Alistair Henry, Senior Director, UCB Celltech

Bohong Zhang, Director, Head of Protein Production, Discovery Therapeutics, Shire Pharmaceuticals Inc.

Orla Cunningham, Director, Biomedicine Design, Pfizer, Inc.

Daniel Lightwood, Director, Antibody Discovery, UCB

W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie

Ercole Rao, Head Engineered Protein Therapeutics, Sanofi

Vivian Lindo, Associate Director, Product Characterisation, MedImmune

Ralf Schumacher, Global Head Bioprocess and Pharmaceuticals Development, Boehringer Ingelheim

Thorsten Lorenz, Group Head, Developability Assessment Biologics, Novartis

Alexey Rak, Head of Bio Structure and Biophysics, Sanofi

Thomas Jostock, Group Head, Cell Line Development, Novartis

Donmienne Leung, Principal Research Scientist, Eli Lilly

Dasa Lipovsek, Senior Principal Scientist, Bristol-Myers Squibb

Matthew Beard, Senior Principal Scientist, Ipsen

Antonietta Impagliazzo, Principal Scientist, Janssen

Felix Schiele, Principal Scientist, Boehringer Ingelheim

James Hunt, Team Leader, AstraZeneca

Darko Skegro, Senior Team Leader, Novartis

Tilman Schlothauer, Group Leader, Roche Pharma Research and Early Development

Shirley Peters, Senior Scientist, Antibody and Protein Engineering and Design, UCB

Whitney Shatz, Senior Research Scientist, Genentech

Caroline Colley, Associate Director, Head of Biologics Profiling, Antibody Discovery and Protein Engineering, MedImmune

T. Noelle Lombana, Senior Scientific Researcher in Antibody Engineering, Genentech

William G. Romanow, Senior Associate Scientist, Protein Technologies, Amgen, Inc.

Lothar Germeroth, Senior Vice President and Managing Director, Juno Therapeutics

Antonin de Fougerolles, Chief Scientific Officer, Ablynx

Veronique Lecault, Co-founder, AbCellera

Jens Frauenfeld, Chief Executive Officer, Salipro Biotech AB

Mihriban Tuna, Vice President, Discovery, F-star Biotechnology Ltd.

Thomas Sandal, Vice President R&D, Crescendo Biologics

Joachim Feldwisch, Director Preclinical Development, Affibody AB

Mikael Mattsson, Director Antibody Discovery, BioInvent International AB

James Errey, Associate Director, Biomolecular Structure, Heptares Therapeutics

Benoit Combaluzier, Head of Antibody Discovery, Neurimmune Therapeutics

Pierre Moretti, Head of Cell Line Development, Glenmark Pharmaceuticals SA

Sven Berger, Head of Mammlian Expression, Pieris Pharmaceuticals

Peter Molloy, Senior Group Leader, Immunocore

Alan L. Epstein, Professor of Pathology, USC Keck School of Medicine

Naomi Chayen, Professor of Biomedical Sciences, Imperial College London

Yoram Reiter, Professor, Israel Institute of Technology

Paul Dalby, Professor of Biochemical Engineering and Biotechnology, University College London

Manfred Konrad, Research Director, Enzyme Biochemistry Laboratory, Max Planck Institute for Biophysical Chemistry

For more information please contact marketing@oxfordglobal.co.uk

2017 Confirmed Sponsors Include:

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day One – 24th April 2017

07.30 – 08.05 Registration

08.05 – 08.10 Oxford Global’s Welcome Address

08.10 – 08.15 Chairperson’s Opening Address

08.15 – 09.00 Co-located Event Keynote Address: The Human Secretome Project – A Combination Of Phenotypic And Target-based Drug Discovery Strategies Use of secreted and transmembrane proteins as drug targets for antibodies and small molecules

Generation of the human secretome, a set of 6400 different human proteins in their active state

Phenotypic and target-based screening of the ‘AZ/KTH secretome library’ in biological effect assays

Lorenz Mayr, Vice President, Biological Reagents & Assay Development, AstraZeneca

Advances In Protein Engineering, Design & Selection Antibody Biotherapeutics

09.00 – 09.30 Stream Keynote Address: Targeting Bi-specific Biologics To Disease Tissues The development of clinically validated bi-specific biologics platforms such as dual

variable domain immunoglobulins (DVD-Igs) has permitted the exploration of tissue specific and disease tissue specific targeting of biologics.

We will describe preclinical examples of tissue targeting in normal and disease in vivo models as part of a new generation of locally acting “regio-specific” biologics therapies

Andrew Goodearl, Director, AbbVie

Therapeutic Antibody Selection And Application Lead therapeutic antibody selection at Genentech

Case studies for application

Yan Wu, Director and Principal Scientist, Genentech

09.30 – 10.00 Streamlined Process Development And Characterisation Through The Use Of High-Throughput Analytics Current and new approaches to high throughput analytics at Lonza

Product quality and impurity analytics approach for rapid Process Development

Small scale purification development support using a high throughput impurity testing method

Hemisha Patel, Group Leader, Process Analytics, Lonza

Computational Approaches in Antibody Design: Identifying And Reducing Liabilities Early In The Discovery Process Computational tools facilitating antibody optimization have improved greatly in recent years. These tools are finding increasing acceptance for liability assessment and reduction early in the discovery process. Using the BioLuminate software platform, we describe both how these calculations can be utilized for workflowed triage among multiple candidates, and how tools such as FEP can be used to suggest sequence engineering that can ameliorate identified liabilities (e.g. aggregation propensity) while maintaining affinity and stability.

David Pearlman, Senior Principal Scientist, Schrödinger

10.00 – 11.20 Morning Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x3

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day One – 24th April 2017

11.20 – 11.50 Boosting Protection Via Protein Engineering: The Case Of Influenza

Hemmaglutinin The ultimate goal of influenza vaccinology is the development of a universal influenza

vaccine that provides protection against a wide range of influenza viruses

Through an iterative process of rational design and library approach we designed and produced in mammalian cells an immunogen group 1 influenza hemagglutinin (HA) that fully resembles only the conserved stem of HA with excellently preserved native conformation

During this process the correlation between epitope stability and protective ability of the antigen appear evident

The most advanced candidate with structural properties comparable to those of full-length HA and demonstrated its unique ability to elicit broad and protective immune response in mice and nonhuman primates

Antonietta Impagliazzo, Principal Scientist, Janssen

Efficient Mining Of The B Cell Repertoire – Finding Rare Antibodies With Desirable Characteristics UCB’s core antibody discovery technology enables extremely efficient interrogation of the natural

antibody repertoire

The platform combines high throughput B cell culture screening and a proprietary technique called the “fluorescent foci method” to identify and isolate single, antigen-specific, IgG-secreting B cells

We will describe the technology and provide examples of how we have applied the platform to a range of antibody discovery projects

Daniel Lightwood, Director, Antibody Discovery, UCB

11.50 – 12.20 Translating Discovery Knowledge Into Process Design Ralf Schumacher, Global Head Bioprocess and Pharmaceuticals Development, Boehringer Ingelheim

A Bi-Specific Centyrin Targeting EGFR And c-Met Inhibits Cellular Signaling Through Avidity Kristen Picha, Scientific Director, Janssen BioTherapeutics, Janssen R&D

12.20 – 12.50 Modeling Protein-Protein Interactions With First-Principles Docking Computer modeling of protein-protein interactions plays an increasingly important role in studies of biologics. This work presents a novel algorithm for predicting likely antigen epitopes from protein-protein docking results using the MOE software package. Protein structures are represented by a coarse-grained bead model which accurately reproduces the interaction energies of the corresponding all-atom model. An additional aggregation scoring term is provided by mapping hydrophobic patches derived from surface analysis onto the model structure. Automated sequence annotation is used to identify the antibody complementarity-determining regions to further constrain the docked poses. This approach generates good poses ranked in the top 100 in over 80% of the cases in the ZDOCK benchmark test set, a result superior to comparable published methods. Protein-protein residue contacts are then used to generate interaction fingerprints which serve to identify Boltzmann-weighted clusters of poses from which to extract consensus epitope residues. Using this method, at least one predicted epitope from the top-ranked five clusters has significant overlap with the native structure in over 50% of test cases.

Essam Metwally, Senior Scientist, Chemical Computing Group

Solution Provider Presentation

12.50 – 13.50 Lunch

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day One – 24th April 2017

13.50 – 14.20 Predicting Long-term Stability And Aggregation Propensity Of Proteins

Using Novel Biophysical Tools Biophysical approaches are routinely used to assess biologics activities, stability and quality. Modern drug discovery operations require characterization of biomolecular interactions to be both time- and cost-effective as well as to be highly precise and reproducible. Here we report applications of two novel methods, nano-Differential Scanning Fluorimetry (nanoDSF) and MicroScale Thermophoresis (MST), that we are applying in our biologics discovery and characterization operations. The examples of the demonstrated effectiveness of the nanoDSF and MST will be presented and discussed.

Alexey Rak, Head of Bio Structure and Biophysics, Sanofi

BiTE® Antibody Constructs For Cancer Therapy Bispecific T-cell engagers

BiTE® antibody constructs

Blincyto®

Nonclinical assessment

Translation into the clinic

Benno Rattel, Executive Director, Amgen

14.20 – 14.50 The Bispecific Challenge: A Novel And Efficient Platform For The Expression Of Bispecific IgGs

Darko Skegro, Senior Team Leader, Novartis

Progress And Challenges With The Isolation And Optimization Of Antibodies – The Good, Bad And Ugly This talk will discuss GSKs progress with the isolation of antibodies for a number of projects using GSKs in vitro and in vivo antibody platforms.

Overview of GSKs Antibody discovery processes

Case studies: some innovative design and selection approaches will be discussed, including isolating antibodies against complex targets such as GPCRs

Rudolf de Wildt, Director, Biopharm R&D & Head of Lead Discovery, GlaxoSmithKline

14.50 – 15.20 Solution Provider Presentation

Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk

15.20 – 16.20 Afternoon Refreshments, Poster Presentation Sessions, One to One Meetings x2

16.20 – 16.50 Engineering A Hexameric Fc For Altered Immune Effector Function Introduction to the design and generation of the multimeric Fc

Use of a “design of experiment” approach to design molecules based on differential FcgR engagement observed for IgG1 or IgG4

Analysis of molecules including FcgR binding and functional cell assays

Shirley Peters, Senior Scientist, Antibody and Protein Engineering and Design, UCB

Advances In Bispecific Antibody Formats: Modelling A New Cross-over Design To Address Novel Biology Modelling and engineering of a new bispecific antibody format

Modulating half-life, valency, and potency, engineering stability

T-cell retargeting, neutralization of targets

Ercole Rao, Head Engineered Protein Therapeutics, Sanofi

16.50 – 17.20 Protein Stabilisation Through Formulation And Protein Engineering, Guided By Computational Methods Computational design and testing of variants of therapeutic proteins with improved

stability

Prediction of formulation excipients for protein stabilization

Paul Dalby, Professor of Biochemical Engineering and Biotechnology, University College London

Expanding The Realm Of Ocular Drug Delivery Using Protein-polymer Conjugates Understanding the role of hydrodynamic size in vitreal clearance

PEGylation as a strategy for half-life extension in the eye

Developing biophysical tools to evaluate protein-polymer candidates

Selection and in-depth characterization of lead candidates

Whitney Shatz, Senior Scientific Researcher, Genentech

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day One – 24th April 2017

17.20 – 17.50 The Salipro System For Stabilization Of Membrane Proteins

Salipro® nanoparticles allow for the reconstitution of membrane proteins in a lipid environment: GPCRs, Transporters, Channels, Receptors

Nanoparticles adjust to size of membrane proteins, incorporation of monomers as well as large homo/hetero-oligomeric complexes

Technology allows to work with membrane proteins in detergent-free buffer systems

Salipro-Membrane-Proteins enable high-resolution cryoEM, structural studies, drug screenings and generation of antibodies

Jens Frauenfeld, Chief Executive Officer, Salipro Biotech AB

Utilising Nanobodies For Immunotherapy Advances in multivalent and multi-specific nanobodies for immune-oncology

Case study: using multi-specific nanobodies to generate the next generation T cell recruiter platform

Case study: improving agonist activity using a multivalent GITR Nanobody

Antonin de Fougerolles, Chief Scientific Officer, Ablynx

17.50 – 18.20 Accessing Natural Diversity For Antibody Discovery Against Membrane Proteins By High-throughput Screening Of Single B Cells Using Direct Cell-binding Assays AbCellera’s rapid, high-throughput platform allows deep screening of natural immune repertoires for antibody discovery from single B cells

Technology is compatible with any species and particularly well suited for the selection of antibodies using direct cell-binding assays

Case studies highlighting successful antibody discovery against membrane proteins, including GPCRs, will be presented

Veronique Lecault, Co-founder, AbCellera

18.20 – 18.50 Juno´s Cell Handling Platform For Efficient Production Of Gene-modified T-Cells Car T cells have shown very promising clinical efficacy in patients with haematological malignancies. Driven by the clinical benefits a substantial future demand has to be satisfied by products with very complex production procedures. Standardization, productivity, and scalability are prerequisites to generate high-quality cell products in sufficient quantities. Juno is developing a cell handling platform which addresses the main questions in car T cell production to meet future demands. New Juno technologies such as T-Catch, Expamers and Streptamers will be discussed in the context of an efficient production platform.

Lothar Germeroth, Senior Vice President and Managing Director, Juno Therapeutics

18.50 – 19.20 The Use Of Bispecific Antibodies To Modulate Anti-tumour Immune Responses Combining immunotherapeutic antibodies for treatment of cancer patients has shown benefits over single agent treatment. An alternative to combining two antibodies is the development of bispecific antibodies that not only bring two biologies together but may result in novel mechanisms of action that are impossible to attain with combinations. A murine-specific anti-LAG-3 and PD-L1 bispecific antibody was engineered which binds both antigens simultaneously and with nanomolar affinities. The anti-LAG-3/PD-L1 bispecific antibody inhibits LAG-3 binding to MHCII and PD-L1 binding to PD-1 and CD80, resulting in T cell activation in an in vitro assay. This potency translates into in vivo efficacy, where the anti-LAG-3/PD-L1 bispecific antibody decreased tumour burden in the MC38 colon carcinoma tumour model, both in early-established or well-established tumours. At the end of the study tumour-free animals were more numerous in the LAG-3/PD-L1 bispecific group than in the group given a combination of individual anti-LAG-3 and PD-L1 antibodies. The results were recapitulated in the CT26 murine colon cancer model, where the LAG-3/PD-L1 bispecific showed an increase of anti-tumour activity as compared to the combination of anti-LAG-3 and anti-PD-L1 antibodies. Thus, the preclinical data supports developing an anti-human LAG-3/PD-L1 bispecific for the treatment of cancer patients.

Mihriban Tuna, Vice President, Discovery, F-star Biotechnology Ltd.

19.20 – 19.50 Engineering An Affibody® Fusion Protein Trap Towards Therapeutic Blocking Of IL-17 In <an Psoriasis is an IL-17 driven disease

An Affibody® based 18.6 kDa ligand trap was engineered to block IL-17A with femtomolar affinity

The trivalent bispecific fusion protein blocks IL-17 with unparalleled affinity and displays long plasma half-life as shown in man

Early development and data from Phase I/II will be presented

Joachim Feldwisch, Director Preclinical Development, Affibody AB

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day One – 24th April 2017

19.50 – 20.20 Broadly Neutralizing Human Monoclonal JC Polyomavirus VP1-Specific Antibodies For The Treatment Of Progressive Multifocal Leukoencephalopathy

Generation of human monoclonal antibodies against JCPyV using the Neurimmune RTMTM technology

Human JCPyV-specific monoclonal antibodies inhibit viral infection in vitro and cross-react against the most common PML-associated mutants

Promising drug candidates for the development of a treatment of PML, a lethal brain disease with a very high unmet medical need

Benoit Combaluzier, Head of Antibody Discovery, Neurimmune Therapeutics

20.20 Networking Drinks End of Day One

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

Conference Room:

Stream Chair:

08.30 -09.00 Keynote Address: Next Generation Of Antibody Drug Conjugates: A Step Forward To Magic Anti-Cancer Bullets Advances in maximizing TI of ADCs

Next generation of cytotoxic warheads

Advances in bispecific ADCs

Translational approaches to ADC Development

Rakesh Dixit, Vice President, Research & Development, MedImmune

Antibody Development, Engineering & Design Cloning, Expression, Purification & Analytics Protein & Antibody Biotherapeutics

09.00 – 09.30 Innovative Antibody Discovery And Optimization Strategies At Bayer Antibody Lead Discovery using in vitro Display

Technologies combined with HT IgG Screening to Select Functional, Biological Active Antibodies Early in the Discovery Process

Phenotypic Antibody Screening to Expand the Functional-Epitope Target Space for Biologics

Example of a Successful Phenotypic Phage Selection and Target Identification for Cancer Cell Internalizing Antibodies to Potentially Develop Novel Antibody Drug Conjugates

Rene Hoet, Vice President, Global Biologics, Bayer

Cloning, Expression, Purification & Analytics Of Recombinant Proteins For Drug Discovery Multiple approaches to improve protein expression

Develop affinity resin for protein purification

Cell line engineering to improve glycosylation of recombinant proteins

Bohong Zhang, Director, Head of Protein Production, Discovery Therapeutics, Shire Pharmaceuticals Inc.

Stream Keynote Address: Recombinant Botulinum Neurotoxins As New Biotherapeutics Botulinum neurotoxins are successful biotherapeutics for

the treatment of several diseases

Recombinant technology provides opportunity to create new toxin based-products to treat diseases in the areas of neurology and beyond

Here we present a case study: creation and characterisation of a recombinant neurotoxin

Matthew Beard, Senior Principal Scientist, Ipsen Bioinnovation

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

09.30 – 10.00 Use Of Synthetic Antibody Libraries For Efficient

Isolation Of Conventional And Bispecific Human mAbs Efficient lead generation using llamdA, a humanized single

domain antibody library

A novel synthetic human antibody Fab library, 4DFab

Combining both solutions enables licensees to create a variety of bispecific biopharmaceutical formats

Guy Hermans, CSO, Isogenica

Antibody Engineering Meets Machine Learning Machine learning provides unambiguous pattern matching

of sequence-function correlation in megadimensional protein space

Gene synthesis allows for efficient and exact creation of systematically varied antibodies designed to explore the relevant space

Applying machine learning on the antibody-set provides detailed information on the relative weight contribution of each amino acid substitution and its synergistic constraint

Modeling of the predicted vs measured antibody activities provides a detailed map of how to engineer the antibodies for improved functionality

Claes Gustafsson, CCO & Co-Founder, DNA 2.0

Solution Provider Presentation

For sponsorship opportunities please contact

sponsorship@oxfordglobal.co.uk

10.00 – 11.00 Morning Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x2

11.00 – 11.30 CDR-restricted Engineering For Antibody Optimization & Humanization Restricting mutation to naturally diverse CDRs allows

maintenance of 100% germline frameworks

CDRs can be manipulated to enable affinity, stability, specificity & solubility optimization

CDRs can be extensively germlined for ultra-humanization whilst maintaining optimal affinity

A number of case studies will be used to highlight these concepts

Orla Cunningham, Director, Biomedicine Design, Pfizer, Inc.

Probing Protein Higher Order Structure With Mass Spectrometry The presentation will examine mass spectrometric methods for gaining information on secondary and tertiary structure of protein biologics, through case studies. Key words: HDX-MS, Cross-linking, ETD, protein structure, mass spectrometry.

Vivian Lindo, Associate Director, Product Characterisation, MedImmune

Adnectins Designed For Therapeutic Applications Adnectins are a family of engineered target-binding proteins

based on the 10th human fibronectin type III domain (10Fn3)

The small size (10 kDa) of Adnectins leads to their fast elimination from the bloodstream

The simple structure and biophysical robustness of Adnectins allows their pharmacokinetics to be modified by chemical conjugation or genetic fusion to longer-lived molecules

This presentation will focus on matching Adnectin format and half-life to the specific application

Dasa Lipovsek, Senior Principal Scientist, Bristol-Myers Squibb

11.30 – 12.00 Solution Provider Presentation

Solution Provider Presentation

Solution Provider Presentation

Reserved – GTP & Novasep

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

12.00 – 12.30 Sampling Human Responses To Design Vaccines

Kalpit Vora, Director, Infectious Disease and Vaccine Based Research, Merck & Co., Inc.

Detecting Antibodies By Liquid Chromatography–Mass Spectrometry

Alistair Henry, Senior Director, UCB Celltech

Updates In The Discovery Of Therapeutic Antibodies Using Phenotypic Screening Mikael Mattsson, Director Antibody Discovery, BioInvent International AB

12.30 – 13.30 Lunch

13.30 – 14.00 Antibodies As Tools In Small Molecule Drug Discovery Therapeutic antibodies have pioneered the modulation of

protein-protein interactions in the clinic

Antibodies are now being used as tools to define specific conformations of target proteins, providing new opportunities for intervention, and enabling the discovery of small molecules which modulate protein-protein interactions

Alastair Lawson, Vice President, Structural Biology, UCB

Combined Vector & Cell Engineering Strategies To Improve The Expression Of Biotherapeutics Thomas Jostock, Group Head, Cell Line Development, Novartis

Bioprocess Development For First-in-class Bispecific Anticalin-antibody Fusion: Fast, Robust And Efficient General descriptions of Anticalins and Anticalin fusion

proteins

Outline of the PRS-343 molecule and its biochemical characteristics

Discussion of the challenges in bispecific process development and advantages of Anticalin fusion proteins

Sven Berger, Head of Mammlian Expression, Pieris Pharmaceuticals

14.00 – 14.30 The Story Of ABT-122 And The Development Of Our First Bispecific DVD-Igs To Enter Clinical Development – How They Shaped Current And Future Bispecific Discovery Strategies Lessons learned from ABT-122 the first DVD-Ig to enter

clinical development

How the second DVD-Ig clinical candidate ABT-981 helped shape our understanding of the DVD-Ig format

How we have taken these lessons and incorporated them into the discovery process to build and screen large libraries of new target pairs

W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie

Recent Developments In Antibody Validation James Hunt, Team Leader, AstraZeneca

A New Molecule Redirecting T-cells Pierre Moretti, Head of Cell Line Development, Glenmark Pharmaceuticals SA

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

14.30 – 15.00 Discovering Antibodies To A Moving Target

In response to infections and irritants, the respiratory epithelium releases the alarmin IL-33 to elicit a rapid immune response. We have recently shown that IL-33 can form intra-chain disulphide bonds resulting in large conformational changes that disrupt the binding of IL-33 to its receptor, ST2. Here we will describe how, through innovative use of mutant forms of IL-33 in antibody phage display selections and appropriate design of screening campaigns, a highly potent inhibitory mAb to IL-33 was identified. This case study is testament to how a fundamental understanding of target structure and biology is key to the identification of potential therapeutic drug candidates.

Caroline Colley, Associate Director, Head of Biologics Profiling, Antibody Discovery and Protein Engineering, MedImmune

Optimizing Antibody Expression By Using Natural Framework Diversity And Host Engineering In A Live Bacterial Antibody Display System Insights into a novel Bacterial Display system using full-

length formats for antibody and antigen in a live cell setting

Ways to improve expression and stability of antibodies in vitro by mimicking the natural antibody selection process, which translates to a mammalian host

Ways to improve antibody expression in host expression strains

T. Noelle Lombana, Senior Scientific Researcher in Antibody Engineering, Genentech

ImmTAC Molecules: Novel Bifunctional Biological Compounds For Targeted Cancer Immunotherapy ImmTAC technology is an immunotherapeutic agent that

targets tumour cells via an affinity-enhanced T cell receptor, coupled with an anti-CD3 effector domain which redirects and activates the host’s polyclonal T cells

ImmTAC molecules are thoroughly tested for their specificity and off-target effects using a robust pre-clinical package which includes antigen-expressing tumour cells and normal cell lines of a matching HLA type

IMCgp100, the first ImmTAC in phase IIa clinical trials, shows a favourable safety profile and durable responses in treating melanoma

Peter Molloy, Senior Group Leader, Immunocore

15.00 – 15.30 Afternoon Refreshments, Poster Presentation Sessions

15.30 – 16.00

LSN3207447, A Bispecific Molecule For The Treatment Of Cancer LSN3207447 binds to Ang2 and VEGFR2 is able to inhibit

angiogenesis

Engineering was required to resolved light chain mis-pairing

Co-targeting of VEGFR2 and Ang2 reduced pathological angiogenesis, inhibited tumor growth and increased survival

Donmienne Leung, Principal Research Scientist, Eli Lilly

Baculovirus Expression Systems In Support Of Structure Studies For Drug Discovery Case studies in producing protein for several challenging

crystallography targets

Production of secreted protein, management of glycosylation states and prevention of lysis

The use of baculovirus as an expression vector system for mammalian cells

William G. Romanow, Senior Associate Scientist, Protein Technologies, Amgen, Inc.

Specific Antidotes For Dabigatran: Structure-guided Affinity Optimization We developed a specific, safe and fast acting antibody

fragment (Fab) to reverse anticoagulant action of dabigatran Rational protein engineering, based on the X-ray structures

led to the optimization of a previously identified candidate molecule with optimized shape complementarity

We also identified another antibody (idarucizumab) which revealed many structural similarities of dabigatran recognition compared with thrombin

Idarucizumab (Praxbind®) gained FDA approval in 2015 for the reversal of dabigatran-induced anticoagulant effects and is the only antidote for a NOAC available to date

Felix Schiele, Principal Scientist, Boehringer Ingelheim

16.00 – 16.30 Small Is Beautiful – Humabodies Drug Conjugates, HDC’s A Real Alternative To ADC’s HDC demonstrate exceptionally fast tumour penetration

HDC facilitate low systemic exposure

Humabodies enable plug and play engineering allowing simple exploration of limitless format options

The versatility of the Humabody™ format enables creation of optimal HDC format and half-life with improved Therapeutic Index

Thomas Sandal, Vice President R&D, Crescendo Biologics

Analytical Fc Receptor Affinity Chromatography For Functional Characterization Fc functionality characterization

New analytical tool

Antibody half-life

Tilman Schlothauer, Group Leader, Roche Pharma Research and Early Development

Novel Fusion Proteins For The Immunotherapy Of Cancer

Alan L. Epstein, Professor of Pathology, USC Keck School of Medicine

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

16.30 – 17.00 Developability Assessment Of Therapeutic

Antibodies – An Integrated Concept For Early Lead Selection The presentation will outline the workflow for antibody candidate assessment to support early lead selection and provide an overview about key physicochemical profiling as well as pre-formulation assays and the application of high throughput technologies in Integrated Biologics Profiling.

Thorsten Lorenz, Group Head, Developability Assessment Biologics, Novartis

Building A Complete Picture: Kinetics, Thermodynamics And Structural Determination Of Stabilised GPCRs Heptares

StaR Technology and Drug Discovery

Expression

Construct Design

Purification

Structural determination

Case studies

Key Steps in purifying membrane proteins

James Errey, Associate Director, Biomolecular Structure, Heptares Therapeutics

Engineering Immune Effector Molecules for Novel Immunotherapy of Cancer and Inflammation The ability to generate highly specific T-Cell receptor Like (TCRL) antibodies which bind HLA-peptide complexes on the surface of cells opens new possibilities in expanding the wealth of therapeutic modalities which targets structures which are derived from intracellular-derived targets. These antibodies can bind specifically to, and kill, the diseased cells. Thus, transform disease-specific targets that are expressed inside malignant cells into targets that can be recognized on the cell surface by soluble TCRL antibodies. Similar approaches can be applied when such TCRL antibodies target autoantigens associated with autoimmunity and inflammation. These approaches expand the pool of novel therapeutic antibodies beyond the limits of currently available antibody-based approaches. The scientific rational as well as specific examples will be presented and discussed.

Yoram Reiter, Professor, Israel Institute of Technology

17.00 – 17.30 Enhancing The Success Of Crystallising Proteins Related To Therapy I will present a variety of practical ways to increase the chances of success by showing

The ideas and inspiration

The rationale

Examples of successful results

Naomi Chayen, Professor of Biomedical Sciences, Imperial College London

Improving Current Enzyme-based Therapy Of Acute Lymphoblastic Leukemia: Molecular Engineering And Directed Evolution Of Human L-asparaginases The enzyme L-asparaginase (L-ASNase) is an approved

drug for the treatment of acute lymphoblastic leukemia (ALL). Depletion of the free amino acid L-asparagine (L-Asn) from the blood stream selectively blocks protein biosynthesis and induces apoptosis of these leukemic cells

The two FDA-approved enzymes are of bacterial origin; they display innocuous side effects mainly attributed to immunogenicity and hypersensitivity reactions

This talk highlights novel approaches for the design and molecular evolution of human L-ASNases that could replace clinically approved bacterial enzymes

We present fabrication of biocompatible nanomaterials serving as microcarriers for protein molecules

Manfred Konrad, Research Director, Enzyme Biochemistry Laboratory, Max Planck Institute for Biophysical Chemistry

17.30 End of Conference

10th Annual Proteins & Antibodies Congress Conference: 24-25 April 2017 Novotel London West, UK

www.proteins-congress.com

HOW TO REGISTER: FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk

Please complete fully and clearly. Please photocopy for additional delegates Title:_____Forename:_______________Surname:________________ Job Title:_________________________________________________ Company/Organisation:_____________________________________ Email:___________________________________________________ Address:_________________________________________________ ________________________________________________________ Postcode: ____________________ Country: ___________________ Direct Telephone ________________ Direct Fax: ________________ Mobile: ________________________ Switchboard: _____________ Signature: ______________________ Date: _____________________

Number of delegates:

Industry del(s) Academic dels(s) Vendor dels(s) Special Offer: 3 for 2

Offer is only valid on the congress and for those registering at Industry or Academic rates

CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number:

Valid from: / Expiry Date: /

Security code:

Cardholders name: _______________________________________

Signature: ______________________________ Date: ___________

PLEASE INVOICE ME:

Invoice Address (if different from above)_______________________

*Please note there is a £50 plus VAT handling charge for payment via invoice *All card payments will be subject to a 3% bank charge or 4% AMEX charge

Registration Fees

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate: Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 + VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to pay-ments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility. Poster Presentations Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size. Cancellation and Curtailment Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation. More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee/ 25% refund Less than 3 months prior to the event Full cancellation fee / No refund Data Protection The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein. Miscellaneous This Agreement may not be transferred or assigned by either the Delegate or the Delegate’s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded.

I agree to the above Terms and Conditions

How to Pay (choose one of the following payment options)

I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies)

Congress £799 plus VAT

1 day pass £499 plus VAT

Day 1 Day 2

Academic Delegates

Congress £499 plus VAT 1 day pass £299 plus VAT Day 1 Day 2

Vendor Delegates (CROs, Consultants, Technology and Service Providers)

Congress Only £1350 plus VAT 1 day pass £799 plus VAT Day 1 Day 2

Poster Presentation £250 plus VAT

PROMOTIONAL LITERATURE DISTRIBUTION

Distribution of your company’s promotional literature to all conference attendees £999 plus VAT

Documentation

I cannot attend but would like to purchase access to the following:

Access to the online conference presentations £499 plus VAT Conference presentations - paper copy £499 plus VAT

VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk

Terms & Conditions of Booking

Delegate Details